These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 2089089)

  • 1. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
    Laux G; Classen W; Sofic E; Becker T; Riederer P; Lesch KP; Struck M; Beckmann H
    J Neural Transm Suppl; 1990; 32():189-95. PubMed ID: 2089089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder.
    Laux G; Beckmann H; Classen W; Becker T
    J Neural Transm Suppl; 1989; 28():45-52. PubMed ID: 2677241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric alterations in treatment with the MAO-A-inhibitor moclobemide.
    Classen W; Laux G
    J Neural Transm Suppl; 1990; 32():185-8. PubMed ID: 2089088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
    Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
    Fritze J; Becker T; Ziegler V; Laux G; Riederer P
    Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha 2-adrenoceptor responsivity in depression: effect of chronic treatment with moclobemide, a selective MAO-A-inhibitor, versus maprotiline.
    Lesch KP; Laux G; Mueller T
    J Neural Transm Suppl; 1990; 32():457-61. PubMed ID: 1965198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.
    König F; Wolfersdorf M
    Pharmacopsychiatry; 1997 May; 30(3):93-6. PubMed ID: 9211570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible monoamine oxidase-A inhibitors in panic disorder.
    Bakish D; Saxena BM; Bowen R; D'Souza J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a reversible monoamine oxidase-A inhibitor versus imipramine in subgroups of depressed patients.
    Bizière K; Berger M
    Acta Psychiatr Scand Suppl; 1990; 360():59-60. PubMed ID: 2248074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression.
    Lotufo-Neto F; Trivedi M; Thase ME
    Neuropsychopharmacology; 1999 Mar; 20(3):226-47. PubMed ID: 10063483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders.
    Priest RG; Gimbrett R; Roberts M; Steinert J
    Acta Psychiatr Scand Suppl; 1995; 386():40-3. PubMed ID: 7717094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study.
    Radat F; Berlin I; Spreux-Varoquaux O; Elatki S; Ferreri M; Puech AJ
    Psychopharmacology (Berl); 1996 Oct; 127(4):370-6. PubMed ID: 8923574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression.
    Lecrubier Y; Guelfi JD
    Acta Psychiatr Scand Suppl; 1990; 360():18-23. PubMed ID: 2248063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moclobemide versus clomipramine in the treatment of depression: a single-centre study, Federal Republic of Germany.
    Funke HJ; Moritz E; Hellstern K; Malanowski H
    Acta Psychiatr Scand Suppl; 1990; 360():46-7. PubMed ID: 2248069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
    Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
    Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moclobemide (Aurorix) in primary major depression.
    Rihmer Z; Barsi J; Vad G; György S; Zalay B; Vég K; Gábor A
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):367-72. PubMed ID: 8208985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of moclobemide compared with maprotiline in treatment of major depressive disorder. A double-blind multicenter study with parallel groups.
    Steinmeyer EM; Vorbach EU; Arnoldt KH
    Pharmacopsychiatry; 1993 Nov; 26(6):246-53. PubMed ID: 8127929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moclobemide (Ro 11-1163) versus imipramine in the treatment of depression.
    Casacchia M; Moll E
    Acta Psychiatr Scand Suppl; 1990; 360():43. PubMed ID: 2248067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.
    Casacchia M; Carolei A; Barba C; Frontoni M; Rossi A; Meco G; Zylberman MR
    Pharmacopsychiatry; 1984 Jul; 17(4):122-5. PubMed ID: 6382361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.